The Committee for Advanced Therapies (CAT) from the European Medicine Agency (EMA) has classified the NK cell technology developed by CiMaas as somatic cell therapy medicinal product with the indication for acute myeloid leukaemia.
After several years of collaboration, Professor Dr Dean Lee has become a formal member of the scientific advisory board of CiMaas as of December 18, 2022.